Who are we?
SciVac Ltd. has the facilities and expertise that enable development of therapeutic proteins starting with a selected clone, through production, purification, and analytical testing. For your phase I and II clinical trials, SciVac Ltd. offers manufacturing services under cGMP conditions.
Development Services
- Production processes in bacteria
- Production processes in mammalian cells
- Purification processes
- Filling processes
- Analytical services
Manufacturing Services Under cGMP conditions
- Production Processes in bacteria or mammalian cells
- Purification processes
- Formulation and Filling processes
- QC release testing
- Manufacturing is suitable for Phase I & Phase II clinical trials
Analytical Development Capabilities
Highly advanced technologies for testing raw materials, in-process controls and release testing in full compliance with EP/USP pharmacopeia and ICH guidelines, such as:
- HPLC
- Immunological Assays
- Colorimetric Electrophoreses
- SDS-PAGE, Western Blot
- Activity/Potency assays
- Bioassays
- Microbiology
- Others, tailored to the client’s needs
SciVac Ltd. Offers
- Experienced scientists and manufacturing professionals
- Effective, robust and timely development
- Modern facilities and state of the art clean rooms
- Proven record for on-time delivery
- Competitive pricing
Drugs Disributed by Scivac Ltd, Israel
Hepatitis Vaccines. Hepatitis B Vaccine 2.5 mcg/0.5 ml, 5 mcg/0.5 ml, 10 mcg/ml. VIALS: 1, 25 x 10 μg/ml. Adults/child
over 10 yrs: 1st dose: At elected date;
2nd dose: 1 mth later; 3rd dose: 6 mths
aft. 1st dose. IM into deltoid muscle.
VIALS: 1, 25 x 2.5 μg/0.5 ml. Child: Birth-
10 yrs. Inject IM into deltoid/anterolat.
thigh.
VIALS: 1 x 25 x 5 μg/0.5 ml. Child: Birth-
10 yrs in highly endemic areas: As
above.
Active immunizat. against hepatit B virus
(HBV) infect.
C/I: Hypersens., acute illness, minor
infect. not C/I. Not to be admin IV.
